29,380 Shares in GoodRx Holdings, Inc. (NASDAQ:GDRX) Acquired by Deutsche Bank AG

Deutsche Bank AG purchased a new position in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 29,380 shares of the company’s stock, valued at approximately $137,000.

Several other institutional investors also recently bought and sold shares of GDRX. Clearbridge Investments LLC purchased a new position in GoodRx during the 4th quarter worth $5,863,000. Raymond James Financial Inc. purchased a new position in GoodRx during the 4th quarter worth $2,500,000. Vanguard Group Inc. increased its holdings in GoodRx by 5.8% during the 4th quarter. Vanguard Group Inc. now owns 8,373,039 shares of the company’s stock worth $38,935,000 after purchasing an additional 460,753 shares during the period. EVR Research LP purchased a new position in GoodRx during the 4th quarter worth $1,761,000. Finally, Dimensional Fund Advisors LP increased its holdings in GoodRx by 22.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,992,311 shares of the company’s stock worth $9,264,000 after purchasing an additional 369,553 shares during the period. 63.77% of the stock is currently owned by hedge funds and other institutional investors.

GoodRx Trading Up 3.1%

Shares of NASDAQ:GDRX opened at $3.94 on Wednesday. GoodRx Holdings, Inc. has a 12-month low of $3.68 and a 12-month high of $9.26. The business’s fifty day simple moving average is $4.27 and its 200-day simple moving average is $4.54. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. The company has a market capitalization of $1.41 billion, a PE ratio of -131.33, a P/E/G ratio of 2.46 and a beta of 1.24.

GoodRx (NASDAQ:GDRX) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.09 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.05. GoodRx had a positive return on equity of 5.35% and a negative net margin of 2.05%. The company had revenue of $202.97 million during the quarter, compared to analysts’ expectations of $202.25 million. During the same quarter in the previous year, the firm posted $0.08 EPS. The firm’s revenue was up 2.6% compared to the same quarter last year. As a group, equities research analysts predict that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have commented on GDRX. The Goldman Sachs Group reduced their price objective on GoodRx from $6.00 to $5.00 and set a “neutral” rating on the stock in a report on Friday, May 9th. UBS Group reduced their price objective on GoodRx from $6.00 to $5.25 and set a “neutral” rating on the stock in a report on Tuesday, May 13th. Wells Fargo & Company reduced their price objective on GoodRx from $8.00 to $7.00 and set an “overweight” rating on the stock in a report on Tuesday, April 29th. Finally, Truist Financial cut their price target on GoodRx from $6.50 to $5.50 and set a “hold” rating on the stock in a report on Thursday, April 10th. Five investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, GoodRx has a consensus rating of “Moderate Buy” and an average price target of $6.55.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.